Loading clinical trials...
Loading clinical trials...
To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Galderma R&D
NCT05414500 · Cutaneous T Cell Lymphoma, Mycosis Fungoides
NCT05589896 · Acute Leukemia, Acute Lymphoblastic Leukemia, and more
NCT07356245 · T-cell Lymphoma, Graft Versus Host Disease, and more
NCT06588868 · Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, and more
NCT06716658 · Lymphoma, T-Cell, NK-LGL Leukemia, and more
Galderma Investigational Site
Orange, California
Galderma Investigational Site
Palo Alto, California
Galderma Investigational Site
Farmington, Connecticut
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions